Various Pharmacogenetic Aspects of Antiepileptic Drug Therapy

No abstract is available for this paper.

• Publication year

  2007

• Venue

  CNS Drugs

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.2165/00023210-200721020-00005PMID 17284096
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clinical factors and ABCB1 polymorphisms in prediction of antiepileptic drug response: a prospective cohort study.

  2006cited by this paper
• Implications of genetic polymorphisms in drug transporters for pharmacotherapy.

  2006cited by this paper
• Clinical implications of CYP3A polymorphisms

  2006cited by this paper
• Single nucleotide polymorphisms in the multidrug resistance 1 gene in Korean epileptics.

  2006cited by this paper
• The potential of pharmacogenetics in the treatment of epilepsy.

  2006cited by this paper
• ABCB1 polymorphisms influence the response to antiepileptic drugs in Japanese epilepsy patients.

  2006cited by this paper
• IN VITRO CHARACTERIZATION OF LAMOTRIGINE N2-GLUCURONIDATION AND THE LAMOTRIGINE-VALPROIC ACID INTERACTION

  2006cited by this paper
• A marker for Stevens-Johnson syndrome …: ethnicity matters

  2006cited by this paper
• Pharmacogenetics of cyclophosphamide in patients with hematological malignancies.

  2006cited by this paper
• Potential Role of Drug Transporters in the Pathogenesis of Medically Intractable Epilepsy

  2005cited by this paper
• Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin.

  2005cited by this paper
• Migraine and other headaches: Associations with Rose angina and coronary heart disease

  2005cited by this paper
• Lack of Association between the C3435T Polymorphism in the Human Multidrug Resistance (MDR1) Gene and Response to Antiepileptic Drug Treatment

  2005cited by this paper
• GABA receptor 1 polymorphism (G1465A) and temporal lobe epilepsy.

  2005cited by this paper
• GABAB Receptor 1 Polymorphism (G1465A) and Temporal Lobe Epilepsy

  2005cited by this paper
• Complex haplotypic effects of the ABCB1 gene on epilepsy treatment response.

  2005cited by this paper
• MDR1 genotype-related pharmacokinetics: fact or fiction?

  2005cited by this paper
• The relationship between the pharmacology of antiepileptic drugs and human gene variation: an overview.

  2005cited by this paper
• UDP Glucuronosyltransferase (UGT) 1A6 Pharmacogenetics: I. Identification of Polymorphisms in the 5′-Regulatory and Exon 1 Regions, and Association with Human Liver UGT1A6 Gene Expression and Glucuronidation

  2005cited by this paper
• UDP Glucuronosyltransferase (UGT) 1A6 Pharmacogenetics: II. Functional Impact of the Three Most Common Nonsynonymous UGT1A6 Polymorphisms (S7A, T181A, and R184S)

  2005cited by this paper
• Speech‐induced Aphasic Seizures in Epilepsy Caused by LGI1 Mutation

  2005cited by this paper
• Drug metabolism and variability among patients in drug response.

  2005cited by this paper
• Variation of hepatic glucuronidation: Novel functional polymorphisms of the UDP‐glucuronosyltransferase UGT1A4

  2004cited by this paper
• Pharmacogenetics – five decades of therapeutic lessons from genetic diversity

  2004cited by this paper
• LGI1 mutations in autosomal dominant partial epilepsy with auditory features

  2004cited by this paper
• Fever, genes, and epilepsy.

  2004cited by this paper
• Pharmacogenetics and enzyme induction/inhibition properties of antiepileptic drugs

  2004cited by this paper
• Levetiracetam in Focal Epilepsy and Hepatic Porphyria: A Case Report

  2004cited by this paper
• Inhibition of multidrug transporters by verapamil or probenecid does not alter blood-brain barrier penetration of levetiracetam in rats.

  2004cited by this paper
• Association of an ABCB1 gene haplotype with pharmacoresistance in temporal lobe epilepsy

  2004cited by this paper
• Monogenic idiopathic epilepsies.

  2004cited by this paper
• Relative impact of covariates in prescribing warfarin according to CYP2C9 genotype.

  2004cited by this paper
• Epilepsy and porphyria: new perspectives.

  2004cited by this paper
• CYP2C polymorphisms, phenytoin metabolism and gingival overgrowth in epileptic subjects.

  2004cited by this paper
• Association of genetic loci

  2004cited by this paper
• A marker for Stevens–Johnson syndrome

  2004cited by this paper
• Pharmacogenetic roles of CYP2C19 and CYP2B6 in the metabolism of R- and S-mephobarbital in humans.

  2004cited by this paper
• Genetic variability in CYP3A5 and its possible consequences.

  2004cited by this paper
• Human UGT1A6 pharmacogenetics: identification of a novel SNP, characterization of allele frequencies and functional analysis of recombinant allozymes in human liver tissue and in cultured cells.

  2004cited by this paper
• Failure to confirm association of a polymorphism in ABCB1 with multidrug-resistant epilepsy

  2004cited by this paper
• Phenobarbital for the Treatment of Epilepsy in the 21st Century: A Critical Review

  2004cited by this paper
• Induction of Drug Metabolism: The Role of Nuclear Receptors

  2003cited by this paper
• GABA(B) receptor 1 polymorphism (G1465A) is associated with temporal lobe epilepsy

  2003cited by this paper
• Pharmacogénétique des réactions médicamenteuses cutanées graves

  2003cited by this paper
• Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women.

  2003cited by this paper
• Increased transcriptional activity of the CYP3A4*1B promoter variant

  2003cited by this paper
• Discovering genotypes underlying human phenotypes: past successes for mendelian disease, future approaches for complex disease

  2003cited by this paper
• Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation

  2003cited by this paper
• Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1.

  2003cited by this paper
• Channelopathies as a genetic cause of epilepsy

  2003cited by this paper
• Human herpesvirus‐6 encephalitis associated with hypersensitivity syndrome

  2003cited by this paper
• Channelopathies as a genetic cause of epilepsy.

  2003cited by this paper
• Inheritance and drug response.

  2003cited by this paper
• Enteroviruses in chronic fatigue syndrome: “now you see them, now you don’t”

  2003cited by this paper
• The genetics of human epilepsy.

  2003cited by this paper
• Pharmacogenomics--drug disposition, drug targets, and side effects.

  2003cited by this paper
• Influence of CYP2C9 genotypes on the formation of a hepatotoxic metabolite of valproic acid in human liver microsomes

  2003cited by this paper
• Clinical relevance of genetic polymorphisms in the human CYP2C9 gene

  2003cited by this paper
• The incidence of alkaptonuria: a study in chemical individuality. 1902 [classical article]

  2002cited by this paper
• A functional polymorphism in the prodynorphin gene promotor is associated with temporal lobe epilepsy

  2002cited by this paper
• Cytochrome P450 Phenotyping/Genotyping in Patients Receiving Antipsychotics

  2002cited by this paper
• Drug resistance in epilepsy: expression of drug resistance proteins in common causes of refractory epilepsy.

  2002cited by this paper
• Pharmacogenetics place in modern medical science and practice.

  2002cited by this paper
• P-glycoprotein-mediated efflux of antiepileptic drugs: preliminary studies in mdr1a knockout mice.

  2002cited by this paper
• Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data.

  2002cited by this paper
• Altered kinetics and benzodiazepine sensitivity of a GABAA receptor subunit mutation [γ2(R43Q)] found in human epilepsy

  2002cited by this paper
• Genetic contribution to variable human CYP3A-mediated metabolism.

  2002cited by this paper
• Role of multidrug transporters in pharmacoresistance to antiepileptic drugs.

  2002cited by this paper
• Polymorphisms for interleukin 1 beta exon 5 and interleukin 1 receptor antagonist in Taiwanese children with febrile convulsions.

  2002cited by this paper
• Identification of a psoriasis susceptibility candidate gene by linkage disequilibrium mapping with a localized single nucleotide polymorphism map.

  2002cited by this paper
• Common allelic variants of cytochrome P4503A4 and their prevalence in different populations.

  2002cited by this paper
• The human ATP-binding cassette (ABC) transporter superfamily.

  2001cited by this paper
• Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin.

  2001cited by this paper
• A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms

  2001cited by this paper
• The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement.

  2001cited by this paper
• Pharmacogenetics.

  2001cited by this paper
• First genetic evidence of GABAA receptor dysfunction in epilepsy: a mutation in the γ2-subunit gene

  2001cited by this paper
• Identification of functionally variant MDR1 alleles among European Americans and African Americans

  2001cited by this paper
• Drug delivery via the blood–brain barrier

  2001cited by this paper
• A single nucleotide polymorphism of CYP2b6 found in Japanese enhances catalytic activity by autoactivation.

  2001cited by this paper
• Single-nucleotide polymorphism alleles in the insulin receptor gene are associated with typical migraine.

  2001cited by this paper
• Mutant GABAA receptor γ2-subunit in childhood absence epilepsy and febrile seizures

  2001cited by this paper
• Carbamazepine is not a substrate for P-glycoprotein.

  2001cited by this paper
• Pharmacogenetics of Warfarin Elimination and its Clinical Implications

  2001cited by this paper
• Repeated Neural Tube Defects and Valproate Monotherapy Suggest a Pharmacogenetic Abnormality

  2001cited by this paper
• TNFα promoter region gene polymorphisms in carbamazepine-hypersensitive patients

  2001cited by this paper
• Association study designs for complex diseases

  2001cited by this paper
• Mutant GABA(A) receptor gamma2-subunit in childhood absence epilepsy and febrile seizures.

  2001cited by this paper
• Neurotrophic and neuroprotective actions of estrogens and their therapeutic implications.

  2001cited by this paper
• Severe phenytoin intoxication in a subject homozygous for CYP2C9*3

  2001cited by this paper
• The human ATP-binding cassette (ABC) transporter superfamily.

  2001cited by this paper
• Pharmacogenetics of the human drug-transporter gene MDR1: impact of polymorphisms on pharmacotherapy.

  2001cited by this paper
• Drug transporters in the central nervous system: brain barriers and brain parenchyma considerations.

  2001cited by this paper
• P-Hydroxylation of Phenobarbital: Relationship to (s)-Mephenytoin Hydroxylation (CYP2C19) Polymorphism

  2001cited by this paper
• Drug Glucuronidation in Clinical Psychopharmacology

  2001cited by this paper
• Human epilepsy associated with dysfunction of the brain P/Q-type calcium channel.

  2001cited by this paper
• Multidrug-resistance protein 1 in focal cortical dysplasia.

  2001cited by this paper
• SNPing away at complex diseases: analysis of single-nucleotide polymorphisms around APOE in Alzheimer disease.

  2000cited by this paper
• Pharmacogenetics and the practice of medicine

  2000cited by this paper
• APOE epsilon4 genotype is associated with an earlier onset of chronic temporal lobe epilepsy.

  2000cited by this paper

• Polymorphisms in the Drug Transporter Gene ABCB1 Are Associated with Drug Response in Saudi Epileptic Pediatric Patients

  2023cites this paper
• Learning in Transcriptional Network Models: Computational Discovery of Pathway-Level Memory and Effective Interventions

  2022cites this paper
• Personalized Management of Selected Neurological Disorders

  2020cites this paper
• Genomic sequencing in severe epilepsy: a step closer to precision medicine

  2020cites this paper
• ABCB1 Polymorphisms and Drug-Resistant Epilepsy in a Tunisian Population

  2019cites this paper
• Effects of GRM4, SCN2A and SCN3B polymorphisms on antiepileptic drugs responsiveness and epilepsy susceptibility

  2019cites this paper
• SCN1A and ABCB1 Polymorphisms in Epilepsy

  2018cites this paper
• Association between ABCB1 polymorphisms and response to first-generation antiepileptic drugs in a Tunisian epileptic population

  2018cites this paper
• Pharmacogenomics and pharmacogenetics for the intensive care unit: a narrative review

  2017cites this paper
• Introduction to the Choice of Antiepileptic Drugs

  2015cites this paper
• The pharmacogenomics of epilepsy

  2015cites this paper
• Variations in the Blood Phenytoin Levels during Long-Term Combined Treatment with S-1 and Phenytoin

  2014cites this paper
• Implications of pharmacogenetics for the therapeutic use of antiepileptic drugs

  2014cites this paper
• Population Pharmacokinetics of Phenobarbital in Infants With Neonatal Encephalopathy Treated With Therapeutic Hypothermia*

  2013cites this paper
• Medycyna zindywidualizowana i farmakogenomika w leczeniu schorzeń centralnego układu nerwowego – przyszłość farmakoterapii czy kolejne wyzwanie dla systemu opieki zdrowotnej?

  2013cites this paper
• Principles and Current Issues of Antiepileptic Drug Therapy

  2013cites this paper
• Principles of drug treatment in children.

  2012influential citation
• Anti-epileptic drugs.

  2011cites this paper
• Seizures in Childhood

  2011cites this paper
• Role of genetics and sex steroid hormones in male androgenetic alopecia and female pattern hair loss: An update of what we now know

  2011cites this paper
• Tolerance to the Beneficial Effects of Prophylactic Migraine Drugs: A Systematic Review of Causes and Mechanisms

  2011cites this paper
• Update on the Genetic Polymorphisms of Drug-Metabolizing Enzymes in Antiepileptic Drug Therapy

  2010cites this paper
• Genetic variations and response to antiepileptic drug

  2010cites this paper
• Genetic factors associated with drug-resistance of epilepsy: relevance of stratification by patient age and aetiology of epilepsy.

  2010cites this paper
• The clinical impact of pharmacogenetics on the treatment of epilepsy

  2009influential citation
• [Drugs for status epilepticus treatment].

  2009cites this paper
• Immunemediationof hypersensitivityadversedrug reactions:implicationsfortherapy

  2009cites this paper
• Immune mediation of hypersensitivity adverse drug reactions: implications for therapy

  2009cites this paper
• Champ 6 - pharmacologie des agents utilisés dans l’état de mal épileptique

  2009cites this paper
• Pharmacologie des agents utilisés dans l’état de mal épileptique

  2009cites this paper
• Polymorphisms in the Voltage-gated Sodium Channel Genes and Antiepileptic Efficacy of Carbamazepine

  2009cites this paper
• Gene-to-Gene Interaction between Sodium Channel-Related Genes in Determining the Risk of Antiepileptic Drug Resistance

  2009cites this paper
• [Drug resistance in partial epilepsy: epidemiology, mechanisms, pharmacogenetics and therapeutical aspects].

  2008cites this paper
• La pharmacorésistance des épilepsies partielles : épidémiologie, mécanismes, pharmacogénétique, perspectives thérapeutiques

  2008cites this paper
• Voltage-gated sodium channel Nav1.1, Nav1.3 and beta1 subunit were up-regulated in the hippocampus of spontaneously epileptic rat.

  2008cites this paper
• Farmacogenética e antiepilépticos (farmacologia das drogas antiepilépticas: da teoria à prática)

  2008cites this paper
• Statistical methods for examining genetic influences of resistance to anti-epileptic drugs

  2008cites this paper
• [Pharmacogenetics in Parkinson's disease treatment].

  2008cites this paper
• The first case of phenytoin intoxication associated with the concomitant use of phenytoin and TS-1, a combination preparation of tegafur, gimeracil, and oteracil potassium

  2008cites this paper
• Should we be 'pushing meds'? The implications of pharmacogenomics.

  2008cites this paper